Last reviewed 2026-05-17 · How we verify

Charles Mel Wilcox, MD — Portfolio Competitive Intelligence Brief

Charles Mel Wilcox, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

Therapeutic area mix

• Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
2. AstraZeneca · 1 shared drug class
3. AstraZeneca (originally Astra AB) · 1 shared drug class
4. Baxter · 1 shared drug class
5. China-Japan Friendship Hospital · 1 shared drug class
6. Chinese University of Hong Kong · 1 shared drug class
7. Cinclus Pharma Holding AB · 1 shared drug class
8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Charles Mel Wilcox, MD:

• Charles Mel Wilcox, MD pipeline updates — RSS
• Charles Mel Wilcox, MD pipeline updates — Atom
• Charles Mel Wilcox, MD pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Charles Mel Wilcox, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/charles-mel-wilcox-md. Accessed 2026-05-17.

Related

• Charles Mel Wilcox, MD full company profile
• All CI briefs
• Build a custom feed